The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 05, 2012
Filed:
Apr. 16, 2007
Sungtaek Lim, Flemington, NJ (US);
Keith John Harris, Chester, NJ (US);
David Stefany, Hillsborough, NJ (US);
Charles J. Gardner, Royersford, PA (US);
Bin Cao, Bedminster, NJ (US);
Ray Boffey, Harlow, GB;
Timothy A. Gillespy, Hillsborough, NJ (US);
Joacy C. Aguiar, Newark, NJ (US);
Hazel J. Dyke, Harlow, GB;
Elsa A. Dechaux, Harlow, GB;
Sungtaek Lim, Flemington, NJ (US);
Keith John Harris, Chester, NJ (US);
David Stefany, Hillsborough, NJ (US);
Charles J. Gardner, Royersford, PA (US);
Bin Cao, Bedminster, NJ (US);
Ray Boffey, Harlow, GB;
Timothy A. Gillespy, Hillsborough, NJ (US);
Joacy C. Aguiar, Newark, NJ (US);
Hazel J. Dyke, Harlow, GB;
Elsa A. Dechaux, Harlow, GB;
Aventis Pharmaceuticals Inc., Bridgewater, NJ (US);
Abstract
The present invention is directed to a compound of Formula (I) wherein Cy, Cy, L, L, and Rare as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).